Thea Pharma Us

Thea Pharma Us company information, Employees & Contact Information

Explore related pages

Related company profiles:

Established in Lexington, Massachusetts in 2019, Thea Pharma, Inc., is the United States subsidiary of Théa. Its product offering is comprised of a portfolio of seven leading eye-care products that are regulated or approved by the U.S. Food and Drug Administration (FDA), including Zioptan®, AcellFX™, Cosopt®, Cosopt® PF, Azasite®, Akten®, and Betimol®, iVIZIA dry-eye drops and eyelid hygiene products, and now IYUZEH™. By focusing our passion and expertise within the U.S. market, Thea Pharma's goal is to deliver uncompromising care that allows all stakeholders to envision the future of ophthalmic treatment with eyes wide open. To learn more about Thea Pharma, Inc., visit https://theapharmainc.com.

Company Details

Employees
110
Founded
-
Address
303 Wyman St,
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Waltham, Massachusetts
Looking for a particular Thea Pharma Us employee's phone or email?

Thea Pharma Us Questions

News

Thea Pharma Inc. Launches Preservative Freedom Coalition to Advocate for Preservative-free Eye Care - PR Newswire

Thea Pharma Inc. Launches Preservative Freedom Coalition to Advocate for Preservative-free Eye Care PR Newswire

Théa Completes its Acquisition of Akorn’s Branded Ophthalmic Products Expanding its Presence in the United States Eye Care Industry - Business Wire

Théa Completes its Acquisition of Akorn’s Branded Ophthalmic Products Expanding its Presence in the United States Eye Care Industry Business Wire

Thea Pharma Inc. Launches IYUZEH™ (latanoprost ophthalmic solution) 0.005% in the U.S. - PR Newswire

Thea Pharma Inc. Launches IYUZEH™ (latanoprost ophthalmic solution) 0.005% in the U.S. PR Newswire

Thea Pharma Announces FDA Approval of IYUZEH™ for the Reduction of Elevated Intraocular Pressure (IOP) in Patients with Open-angle Glaucoma or Ocular Hypertension - Business Wire

Thea Pharma Announces FDA Approval of IYUZEH™ for the Reduction of Elevated Intraocular Pressure (IOP) in Patients with Open-angle Glaucoma or Ocular Hypertension Business Wire

Top Thea Pharma Us Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant